Market Movers: Charles River Laboratories (CRL) Climbs 5.13% to Close at $220.58 June 23

Equities Staff  |

Charles River Laboratories International Inc. (NYSE:CRL) stock was among today's market movers, ending trading higher 5.13% to $220.58 on June 23.

451,912 shares traded hands while the 30-day daily average of 514,997 shares.

The company's stock has climbed 44.31% so far in 2022.

Charles River Laboratories shares have fluctuated between $203.37 and $460.21 over the past twelve months.

The company is set to release earnings on 2022-08-03.

For technical charts, analysis, and more on Charles River Laboratories visit the company profile.

About Charles River Laboratories International Inc.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

To get more information on Charles River Laboratories International Inc. and to follow the company's latest updates, you can visit the company's profile page here: Charles River Laboratories International Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content